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ABSTRACT  
BACKGROUND: Pneumocystis jiroveci pneumonia in HIV-negative immunocompromised 
patients is associated with high mortality rates. Although trimethoprim-sulfamethoxazole 
(TMP-SMX) provides a very effective prophylaxis, pneumocystosis still occurs and may even 
be emerging, due to sub-optimal characterization of patients most at risk, hence precluding 
targeted prophylaxis.      
METHODS: We retrospectively analyzed all cases of documented pneumocystosis in HIV-
negative patients admitted in our institution, a referral center in the area, from January 1990 to 
June 2010, and extracted data on their underlying condition(s). To estimate incidence rates 
within each condition, we estimated the number of patients followed-up in our area for each 
condition, by measuring the number of patients admitted with the corresponding international 
classification diagnostic code, through the national hospital discharge database (PMSI).  
RESULTS: From 1990 to 2010, 293 cases of pneumocystosis were documented, of whom 
154 (52.6%) tested negative for HIV. The main underlying conditions were hematological 
malignancies (32.5%), solid tumors (18.2%), inflammatory diseases (14.9%), solid organ 
transplant (12.3%), and vasculitis (9.7%). Estimated incidence rates could be ranked in three 
categories: i) high risk (incidence rates > 45 cases per 100,000 patient-year): polyarteritis 
nodosa, granulomatosis with polyangiitis, polymyositis/dermatopolymyositis, acute leukemia, 
chronic lymphocytic leukemia, and non-Hodgkin lymphoma; ii) intermediate risk (25-45 
cases per 100,000 patient-year): Waldenström macroglobulinemia, multiple myeloma, and 
central nervous system cancer; and iii) low risk (< 25 cases per 100,000 patient-year): other 
solid tumors, inflammatory diseases, and Hodgkin lymphoma. 
CONCLUSIONS: These estimates may be used as a guide to better target pneumocystosis 
prophylaxis in the groups most at risk.
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Pneumocystis jiroveci pneumonia in human immunodeficiency virus (HIV)-negative patients 
has a poor prognosis with in-hospital mortality rates of 50%, reaching 86% in patients with 
acute respiratory distress syndrome.
1,2
 The high level of protection conferred by 
trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis suggests that extended use of this 
drug may decrease the burden of pneumocystosis in non-HIV immunocompromised patients.
3
However, the wide spectrum of immunosuppressive conditions predisposing to 
pneumocystosis, and the limited data available on its incidence in non HIV-infected patients, 
has precluded the establishment of evidence-based guidelines for pneumocystosis prophylaxis 
in these populations. 
In HIV-infected patients, CD4 cells count in peripheral blood provides a simple and 
accurate method to determine the risk of pneumocystosis,
4
 which led to the recommendations 
that TMP-SMX be initiated in any patient with CD4 counts < 200 cells/l, or 15%.
5
 For HIV-
negative patients, the accuracy of this biomarker is poorly characterized. The level of 
immunosuppression results from both the impairment in immunity related to the underlying 
disease itself, and from the immunosuppressive effect of drugs used to control these diseases, 
particularly corticosteroids. In this regard, the American Thoracic Society (ATS) advises to 
consider prophylaxis when prednisone dose exceeds 20 mg/day for longer than 1 month, but 
acknowledges that this is not evidence-based.
5
 Of note, this statement does not take into 
account the heterogeneity of pneumocystosis risk across the wide spectrum of diseases in 
which corticosteroids are used. For example, the incidence of pneumocystosis among patients 
on corticosteroids is higher in granulomatosis with polyangiitis (formerly known as Wegener 
granulomatosis), than in rheumatoid arthritis.
6
 We aimed to provide original data on the 
spectrum of diseases associated with pneumocystosis in non-HIV infected patients, and to 
estimate the incidence of pneumocystosis in these conditions, in order to better inform the 
targeted use of TMP-SMX prophylaxis in HIV-negative patients at higher risk. 
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MATERIALS AND METHODS 
Pneumocystosis case definitions 
We performed a retrospective analysis of all patients with pneumocystosis admitted from 
January 1990 to June 2010 to the Rennes University Hospital, a tertiary care teaching hospital 
which serves as the referral center for the area (catchment population estimated at one million 
inhabitants). A case was defined by a positive direct examination (May-Grunwald-Giemsa, 
Gomori-Grocott staining, or immunofluorescence) on bronchoalveolar lavage. Cases of 
pneumocystosis documented only by PCR were not included.
7
 Only patients tested HIV-
negative were included. Patients were identified through: i) the computerized database of the 
department of infectious diseases and intensive care unit (ICU); ii) the database of the 
parasitology-mycology laboratory, which serves as the reference center for pneumocystosis 
diagnosis in the area, and iii) the hospital discharge database from the Program of 
Medicalization of the Information System (PMSI), using the International Classification of 
diseases, 9
th
 Revision, Clinical Modification (ICD-9-CM), code 136.3, and ICD-10-CM, code 
J17.3. We only analyzed the first hospitalization when pneumocystosis diagnosis was 
mentioned. Information filled at discharge includes the major cause of admission and 
associated conditions. Underlying conditions were selected based on experts' discussions and 
literature knowledge. Considering the high diversity of conditions, and in order to provide a 
description relevant for clinical practice, a hierarchization was applied to assign only one 
underlying condition per patient. If a patient had > 1 underlying condition, the case was 
assigned to the condition considered to be the most immunosuppressive. The selection started 
with hematological malignancies, solid organ transplant, solid tumors, vasculitis, systemic 
inflammatory diseases, and ended with miscellaneous conditions. Following this hierarchy, a 
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case presenting, for instance, with non-Hodgkin lymphoma and lupus, was recorded as non-
Hodgkin lymphoma.  
Incidence rates of pneumocystosis according to underlying conditions 
To estimate the incidence rates in each condition, we had to estimate the denominator (i.e. the 
number of patients followed in our geographic area for each condition over the study period). 
We performed a retrospective analysis of all patients hospitalized in our institution during the 
study period, by searching discharge diagnosis for the corresponding ICD-9/10-CM codes: 
non-Hodgkin lymphoma (202.8, C85.9), chronic lymphocytic leukemia (204.1, C91.1), acute 
leukemia (205.0, C92.0), hematopoietic stem cell transplant (Z948.0, Z948.1), multiple 
myeloma (203.0, C90.0), Hodgkin lymphoma (201, C81), Waldenström macroglobulinemia 
(273.3, C88.0), central nervous system cancer (191, C71), breast cancer (174, C50), lung 
cancer (162, C34), rheumatoid arthritis (714.9, M05.8, M06.9), polymyalgia rheumatica 
(725.0, M35.3), Sjögren syndrome (710.2, M35.0), polymyositis (710.4, M33.2) and 
dermatomyositis (710.3, M33.9) merged in a single category,  granulomatosis with 
polyangiitis (446.4, M31.3), polyarteritis nodosa (446.0, M30.0), giant cell arteritis (446.5, 
M31.6), and sarcoidosis (135.0, D86).  
Data analysis 
An estimate of the incidence rates of pneumocystosis in each condition was derived by 
dividing the number of cases documented in this group by the number of patients followed-up 
for this condition in our institution over the study period, and then by the study duration (20.5 
years). Underlying conditions were ranked according to the estimated incidence rates of 
pneumocystosis. For solid tumors, we only calculated incidence rates if there was > 1 case of 
pneumocystosis per cancer type. Categorical variables were expressed as proportion and 
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compared using Chi-square test or Fisher’s exact test, as appropriate. A P value < .05 was 
considered statistically significant. 
RESULTS 
Pneumocystosis cases in non HIV-infected patients 
From January 1990 to June 2010, 293 cases of pneumocystosis were documented. Among 
them, there were slightly more cases in non HIV-infected patients (n=154, 52.6%), than in 
HIV-infected patients (n=139, 47.4%). No significant trend in the incidence was observed in 
HIV-infected cases (46% of patients with pneumocystosis diagnosed during years 1990-1999 
were HIV-infected, vs. 54% during years 2000-2010), and in non HIV-infected patients (46% 
during years 1990-1999, vs. 54% during years 2000-2010), figure 1. The proportion of 
pneumocystosis admitted in ICU was higher in HIV-negative patients than in non HIV-
infected patients (51.9% vs. 28.1%, P = .006). Likewise, in-ICU mortality rates were higher 
in HIV-negative patients than in non HIV-infected patients (52.9% vs. 15.4%, P = .008). 
Underlying conditions of the 154 HIV-negative patients who developed pneumocystosis are 
detailed in table 1. Hematological malignancies represented the most frequent underlying 
condition (32.5%), followed by solid tumors (18.2%), inflammatory diseases (14.9%), solid 
organ transplants (12.3%), and vasculitis (9.7%). All patients with miscellaneous underlying 
conditions (12.3%) where on long term corticosteroid treatment when pneumocystosis 
occurred.  
Prevalence of underlying conditions at risk in the area, and estimated incidence rates of 
pneumocystosis in these conditions 
Among the nearly 120,000 hospitalizations coded each year in our institution during the study 
period, the repartition of patients per underlying condition is detailed in table 1. Data on some 
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conditions were not reliable, either because no specific code exist, because of overlap with 
other diseases, or because the code was created only recently. These include solid tumors 
(pharyngeal cancer or skin cancers, sarcomas), and inflammatory diseases/vasculitis 
(polyneuritis, autoimmune hepatitis, inflammatory bowel disease, Goodpasture syndrome, 
microscopic polyangiitis). Hence, the incidence rates of pneumocystosis could not be 
estimated for these conditions.  
Our estimates of pneumocystosis incidence rates in the main groups at risk varied 
from 2.6 cases per 100,000 patient-year for lung cancer, to 93.2 per 100,000 patient-year for 
polyarteritis nodosa (figure 2). Among transplant recipients, estimates of incidence rates 
varied from 13.7 for heart transplant recipients, to 44.6 per 100,000 patient-year for kidney 
transplant recipients. In the hematological malignancies group, three diseases were 
characterized by high incidence rates (> 45 cases per 100,000 patient-year): non-Hodgkin 
lymphoma, chronic lymphocytic leukemia and acute leukemia, whereas patients with 
Waldenström macroglobulinemia and multiple myeloma had intermediate incidence rates 
(~30 cases per 100,000 patient-year). In the solid tumors group, estimates of incidence rates 
were in the lower range, except for central nervous system cancers with much higher 
incidence rates, estimated at 27.5 cases per 100,000 patient-year (p=0.002). In the 
inflammatory diseases group, pneumocystosis incidence rates were high in patients with 
polymyositis/dermatopolymyositis (53.6 cases par 100,000 patients/year), while other 
inflammatory diseases had incidence rates < 25 cases per 100,000 patient-year. In the 
vasculitis group, estimates of pneumocystosis incidence rates were strikingly high in patients 
with granulomatosis with polyangiitis (71.9 par 100,000 patients/year), despite broad 
recommendations for TMP-SMX use in this disease, and in patients with polyarteritis nodosa, 
the condition associated with the higher incidence rates (93.2 cases per 100,000 patient-year). 
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DISCUSSION 
The main findings of this monocentric retrospective study on the incidence rates of, and the 
risk factors for pneumocystosis, are the followings: i) pneumocystosis remains a significant 
problem in both HIV-positive, and HIV-negative immunocompromised populations, with an 
annual number of cases unabated during the study period; ii) pneumocystosis is more severe 
in HIV-negative patients, as compared to HIV-positive patients, with much higher rates of 
ICU admission, and in-ICU mortality, as previously reported;
8
 iii) hematological 
malignancies represent the main group at risk among non-HIV infected patients, as in other 
cohorts;
9
 iv) the estimated incidence rates of pneumocystosis in non HIV-infected 
immunocompromised patients vary broadly, from 2 to > 90 cases per 100,000 patient-year.  
To our knowledge, this is the first study to provide comparative estimates of the 
incidence rates of pneumocystosis across a wide range of groups at risk: Although previous 
studies estimated the incidence rates in patients with various inflammatory diseases,
10-12
transplant recipients,
6,13
 and cancer,
14
 their heterogeneous designs precluded any comparison 
of the incidence rates from one condition to another. By estimating incidence rates in a broad 
spectrum of groups at risk with the same methodology, this study allows a hierarchical 
classification of groups at risk: Briefly, three inflammatory diseases/vasculitis (polyarteritis 
nodosa, granulomatosis with polyangiitis, and polymyositis/dermatopolymyositis), and three 
hematological malignancies (acute leukemia, chronic lymphocytic leukemia, and non-
Hodgkin lymphoma), are at high risk of pneumocystosis, with incidence rates > 45 cases per 
100,000 patient-year. This suggests that more systematic use of TMP-SMX prophylaxis in 
these patients may be beneficial, especially given the high morbi-mortality associated with 
pneumocystosis in non HIV-infected patients, with ICU admission and in-ICU mortality rates 
at 51.9%, and 52.9%, respectively, in our series. Patients with Waldenström 
macroglobulinemia, multiple myeloma, and central nervous system cancer made up an 
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intermediate group at risk, with incidence rates ranging from 25 to 45 cases per 100,000 
patient-year. In this group, we would recommend that the threshold to initiate pneumocystosis 
prophylaxis be low (i.e. any additional risk factor, such as prolonged use of corticosteroids, 
should prompt TMP-SMX initiation). Lastly, for most patients with solid tumors, 
inflammatory diseases, or Hodgkin lymphoma, estimates of incidence rates are < 25 cases per 
100,000 patient-year, and pneumocystosis prophylaxis should not be routinely recommended. 
These estimates may be used as a guide to better target pneumocystosis prophylaxis. 
The incidence rates of pneumocystosis in solid organ and hematopoietic stem cell 
transplant recipients are much lower in this study than previously reported: Indeed, in the 
absence of prophylaxis, incidence rates were as high as 41,000, 16,000, 14,000, and 11,000 
per 100,000 patient-year, respectively, in heart, hematopoietic stem cell, kidney, and liver 
transplant recipients.
6
 In our institution, TMP-SMX prophylaxis is routinely used during the 
first 6-12 months post-transplant, as recommended by the American Society of 
Transplantation,
15
 the Kidney Disease Improving Global Outcomes Transplant Work Group,
16
and the Infectious Diseases Society of America/American Society of Blood and Marrow 
Transplantation guidelines for hematopoietic stem cell transplant recipients.
17
 We only 
observed pneumocystosis in transplant recipients not receiving TMP-SMX, either because of 
severe intolerance, non-adherence, erroneous discontinuation, or in patients who were 
transplanted more than 6 months earlier (TMP-SMX not routinely indicated anymore). For 
similar reasons, our estimates of pneumocystosis incidence rates in patients with acute 
leukemia or lymphoma are lower than previous estimates dating back from times when TMP-
SMX was not used in these populations (respectively 6,500 and 1,300 cases per 100,000 
patient-year),
14
 probably because patients most at risk (e.g. on fludarabine, R-CHOP, or 
corticosteroids > 20 mg/day), are routinely prescribed TMP-SMX.  
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Our estimates of pneumocystosis incidence rates were much higher in patients with 
central nervous system cancer, than in patients with lung or breast cancer (P = 0.002), as 
previously reported.
18
 This association is usually ascribed to the high doses of corticosteroids 
used for the control of brain tumors-related edema,
19
 and led some experts to recommend 
systematic prophylaxis in patients with malignancies who receive > 20 mg/day of prednisone 
or equivalent, for > 1 month.
18
 Although ATS recommends pneumocystosis prophylaxis in all 
patients with malignancies receiving cytotoxic chemotherapies,
5
 the German Society of 
Hematology and Oncology proposes two levels of recommendations: i) strong evidence (A-I) 
in patients with acute lymphoblastic leukemia, CD4 cells < 200/L, or chronic use of steroids; 
ii) risk status not entirely conclusive (C-III) in patients with chronic neutropenia, acute 
myeloid leukemia, and patients treated with R-CHOP, or high-dose cytarabine.
20
 Although 
fludarabine was not mentioned in these guidelines, this was the only drug associated with 
increased risk of pneumocystosis in patients with lymphoproliferative disorders in a recent 
case-control study.
21
 However, estimates of the risk associated with specific 
immunosuppressive agents are crippled by interactions with the risk associated with the 
underlying conditions, and their regular use in combinations with other immunosuppressive 
agents. Immunosuppressive drugs other than corticosteroids have been associated with 
increased risk of pneumocystosis, including cyclophosphamide,
22
 and prolonged, high-doses 
methotrexate.
23
  Transplant recipients receiving azathioprine or ciclosporine were found at 
lower risk than those on tacrolimus, while limited data are available about the risk associated 
with mycophenolate mofetil or sirolimus use.
24
 Lastly, cases of pneumocystosis have been 
reported in patients treated with rituximab,
25,26
 or tumor necrosis factor alpha inhibitors.
23,27
In a prospective observational study, Mansharamani et al. found that a cut-off at 300 
CD4 cells/L would capture 91% of cases of pneumocystosis in HIV-negative patients,
28
 but 
this cut-off would also capture 39.1% of patients on corticosteroids, most of whom would be 
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unaffected by pneumocystosis. Administering prophylaxis to such large numbers of patients 
would unnecessarily expose patients to drug-related adverse events. Indeed, among all 
patients administered TMP-SMX prophylaxis in a meta-analysis,
29
 the rate of discontinuation 
due to adverse event was 15.2%, with a 3.1% rate of severe adverse events. A risk-benefit 
analysis suggested that only patients with estimated risk of pneumocystosis > 3.5% should be 
initiated on TMP-SMX prophylaxis.
29
Study Limitations 
This study has limitations: Firstly, its monocentric design implies that findings may not be 
replicable in other settings, given the heterogeneity of practices regarding pneumocystosis 
prophylaxis in non-HIV patients, and the variability of pneumocystosis epidemiology. Second, 
given its retrospective design, and the strict inclusion criteria (pneumocystosis had to be 
documented, and recorded), we probably underestimated the actual number of cases. However, 
this underestimation probably affected all conditions at risk, and is thus unlikely to have 
affected their rankings. Lastly, the main limitation resides in the methods used to estimate the 
denominator for the calculation of incidence rates: we assumed that all patients affected by at 
risk conditions would be hospitalized at least once during the study period in our referral 
hospital, and then captured through the hospitalization coding system. This assumption is at 
risk of various biases, including underestimation of the denominator (e.g. patients only 
followed as outpatients, or admitted elsewhere; coding errors), or overestimation (e.g. patients 
who died or moved to another area remained in the denominator, although no more at risk of 
being admitted for pneumocystosis in our institution).  
CONCLUSIONS 
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Despite these limitations, this study is the first to provide comparative estimates of 
pneumocystosis incidence rates across a broad spectrum of conditions at risk in non-HIV 
infected patients. Our findings may be used to better target pneumocystosis prophylaxis 
according to the level of risk: low for most solid tumors and inflammatory diseases, and for 
Hodgkin lymphoma; intermediate for Waldenström’s macroglobulinemia, multiple myeloma, 
and patients on corticosteroids for brain tumors; and high for polyarteritis nodosa, 
polymyositis/dermatopolymyositis, granulomatosis with polyangiitis, acute leukemia, chronic 
lymphocytic leukemia, and non-Hodgkin lymphoma. This approach should decrease the 
burden of pneumocystosis in HIV-negative patients. 
Acknowledgements: We are indebted to Frederic Balusson who extracted the data from the 
PMSI system. 
Figure legends 
Figure 1 Cases of Pneumocystis jiroveci pneumonia diagnosed from January 1990 to June 2010 
Figure 2 Estimated incidence of Pneumocystis jiroveci pneumonia among groups at risk
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Table 1 Main underlying conditions in 154 consecutive cases of Pneumocystis jiroveci pneumonia in 
non HIV-infected patients, and number of patients hospitalised with this condition (1990-2010) 
Underlying condition 
Number of 
pneumocystosis cases 
n (% of total cases in 
non-HIV patients)
Total number of 
patients with the 
underlying condition  
Haematological malignancies 50 (32.5%) 6 035 
- Non-Hodgkin lymphoma 
- Chronic lymphocytic leukemia 
- Acute leukemia 
- Haematopoietic stem cell transplant 
- Multiple myeloma 
- Hodgkin lymphoma 
- Waldenström macroglobulinemia 
19 
11 
8 
5 
3 
2 
2  
2 006 
1 030 
730 
638 
480 
812 
339 
Solid tumours 28 (18.2%) 
- Central nervous system cancer 
- Breast cancer 
- Lung cancer 
- Pharyngeal cancer 
- Skin cancer 
- Sarcoma 
- Esophagus, kidney, thymus, adrenal 
gland, cholangiocarcinoma 
7 
6 
3 
3 
2 
2 
One patient each 
1 242 
3 600 
4 879 
Inflammatory diseases 23 (14.9%) 
- Rheumatoid arthritis 
- Goodpasture syndrome 
- Polymyalgia rheumatica 
- Polymyositis/dermatopolymyositis 
- Polyneuritis 
- Sjögren syndrome 
- Sarcoïdosis 
- Inflammatory bowel disease 
- Auto-immune hepatitis 
8 
3 
3 
2 
2 
2 
One patient each 
1 574 
1 235 
182 
                 
488 
1 269 
Solid organ transplant 19 (12.3%) 
- Kidney 
- Liver  
- Heart 
- Lung 
11 
6 
One patient each 
1203 
1329 
357 
25 
Vasculitis 15 (9.7%) 
- Granulomatosis with polyangiitis 
- Microscopic polyangiitis 
- Polyarteritis nodosa 
- Giant cell arteritis 
5 
4 
3 
3 
339 
157 
1 277 
Miscellaneous 19 (12.3%) 
- Glomerulonephritis 
- Interstitial lung disease 
- Acute alcoholic hepatitis 
- Cirrhosis 
- Congenital immunodeficiency 
- Hydatiform mole, post-radiation 
myelitis, cryptogenic organizing 
pneumonia, acute cophosis 
- Other causes with long term 
corticotherapy 
5  
2 
2 
2 
2 
One patient each 
2 
HIV = human immunodeficiency virus 
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Table 2 Logistic regression analysis of pneumocystosis incidence taking as a reference the 
group of patients with breast or lung cancer (n = 3600 + 4879 patients)
Risk of pneumocystosis Odds Ratio [CI95%] P  
High risk  
- Polyarteritis nodosa  
- Granulomatosis with polyangeitis  
- Polymyositis/dermatomyositis  
- Non-Hodgkin lymphoma 
- Chronic lymphocytic leukemia  
- Acute leukemia 
 18.3 [4.9-63.4] 
14.1 [1.7-42.3] 
10.5 [2.2-48.7] 
9.0 [4.1-19.2] 
10.2 [4.2-24.6] 
10.4 [4.0-24.6] 
<0.0001 
<0.0001 
0.0028
<0.0001 
<0.0001 
<0.0001
Intermediate risk  
- Waldenström macroglobulinemia 
- Multiple myeloma  
- Central nervous system cancer 
5.6 [1.2-25.9] 
5.9 [1.6-21.9] 
5.3 [2.0-14.8] 
0.0282
0.0078
0.0009
Low risk 
- Rheumatoid arthritis 
- Polymyalgia rheumatica 
- Horton granulomatosis 
- Hodgkin lymphoma 
- Sjögren syndrome 
- Sarcoïdosis 
4.8 [1.85-12.5] 
2.3 [0.6-8.5] 
2.2 [0.6-8.2] 
2.3 [0.5-10.8] 
1.9 [0.2-15.3] 
0.7 [0.1-5.8] 
0.0012
0.2140
0.2331
0.2813
0.5324
0.7773
CI95% = confidence interval 95% 
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Figure 1 Cases of Pneumocystis jiroveci pneumonia diagnosed from January 1990 to June 2010 
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Figure 2 Estimated incidence of Pneumocystis jiroveci pneumonia among groups at risk
Incidence of pneumocystosis (per 100 000 patients-year) 
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CLINICAL SIGNIFICANCE
• This observational study found that the risk of pneumocystosis in 
immunocompromised HIV-negative patients is particularly high (incidence > 45 cases 
per 100,000 patient-year) in patients with polyarteritis nodosa, granulomatosis with 
polyangiitis, polymyositis/dermatopolymyositis, acute leukemia, chronic lymphocytic 
leukemia, and non-Hodgkin lymphoma. 
• Other malignant and inflammatory diseases were at lower risk. 
• These estimates may be used to better inform the targeted use of trimethoprime-
sulfamethoxazole prophylaxis in HIV-negative patients. 
